- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15.11. | Halozyme bids for Evotec; BeiGene gets a new name | ||
| 14.11. | Trump names RFK Jr. as his pick to lead HHS | ||
| 14.11. | Eisai wins over European regulators on Alzheimer's drug Leqembi | ||
| 14.11. | PTC wins US approval of gene therapy for fatal enzyme disorder | ||
| 14.11. | Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy | ||
| 13.11. | Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing | ||
| 13.11. | Metsera raises $215M to accelerate obesity drug plans | ||
| 13.11. | TRex Bio raises $84M to compete in crowded immune drug field | ||
| 13.11. | BioNTech to buy Biotheus, gaining control of cancer bispecific | ||
| 12.11. | GSK partners with Flagship startup to hunt for Parkinson's drugs | ||
| 12.11. | Biotech investors, including Third Rock, pump $100M into a startup's genetic medicine for ALS | ||
| 12.11. | Neurogene hits a setback in the clinic, one week after raising funds | ||
| 12.11. | AstraZeneca, Daiichi revise approval plans for Enhertu successor | ||
| 11.11. | On Wall Street, 'flat out' failure of AbbVie schizophrenia drug leaves analysts stunned | ||
| 11.11. | FDA approves new CAR-T competitor to Gilead's Tecartus | ||
| 11.11. | FDA lifts pause on Novavax flu vaccine trials | ||
| 11.11. | AbbVie's $9B bet collapses as closely watched schizophrenia drug fails studies | ||
| 11.11. | Cigna confirms it is not pursuing Humana acquisition | ||
| 11.11. | Thinking inside the box: How SmartLabs is driving new collaborations to support the life science industry in global innovation hubs | ||
| 11.11. | Fueling accelerated drug development in autoimmune diseases with a modality-agnostic approach | ||
| 11.11. | 7 steps to selecting the right global central lab | ||
| 08.11. | Kalaris to go public via reverse merger with AlloVir | ||
| 08.11. | Athira exploring strategic alternatives after Alzheimer's failure | ||
| 08.11. | Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value | ||
| 08.11. | What RFK Jr.'s influence on Trump could mean for pharma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
